Imigran Juvenil (Sumatriptan)

Sumatriptan is a selective agonist of serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerve endings, thereby interrupting migraine pain pathways.

The specific dose and frequency of Imigran Juvenil are determined by the prescribing healthcare professional based on the patient’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended number of doses per month.

Safety data for sumatriptan in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Imigran Juvenil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran Juvenil delivers sumatriptan via a nasal spray, offering rapid absorption and onset of relief compared with oral tablets. It belongs to the triptan class, which is generally more effective for moderate to severe migraine than non‑specific analgesics, but it shares similar contraindications and drug‑interaction profiles.

Store Imigran Juvenil at room temperature, below 25 °C. Keep the spray in its original container, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Imigran Juvenil is administered as a single spray into one nostril at the first sign of a migraine or cluster headache attack. The patient should remain upright for a few minutes after dosing to facilitate absorption and avoid swallowing the spray.

Serious risks include coronary vasospasm, myocardial infarction, stroke, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic agents. Patients with cardiovascular disease or uncontrolled hypertension should be evaluated carefully before use.

Imigran Juvenil should be avoided in individuals with known hypersensitivity to sumatriptan, uncontrolled hypertension, recent myocardial infarction or stroke, severe peripheral vascular disease, and in patients currently taking MAO inhibitors or other triptans.